Currently, every indication needs to be approved using the "gold standard", a randomized controlled trial, because such trials are considered less biased than observational studies.
Such randomized controlled trials are considered the most rigorous way to conduct a study and the best way to gather convincing evidence of a treatment's effects.
In Data Set A (respectively B), 177 trials (respectively 141 trials) are considered.
Randomised, placebo-controlled, double-blind clinical trials are considered the "gold standard" for clinical research.
In the hierarchy of research designs, the results of randomised controlled trials are considered the highest level of evidence.
An important recent advance has been proposed in [12], where multiple PPSs impinging on non-calibrated arrays, common for practical trials, are considered.
For example, in the health sector, systematic reviews of studies that are based on randomised trials are considered the most robust evidence.
Some important factors in the design of such trials are considered, including history, ethics and law, resources, implementation issues, and complications.
To compare the performances of various EAs, statistical measures like best, mean, standard deviation of results and average computation time, over 20 independent trials are considered.
Randomized controlled clinical trials are considered to provide the highest level of evidence for clinical practice, public health policy and evidence-based systematic reviews.
Applications to sequential clinical trials are considered as well as connections with response-adaptive design of experiments in a Bayesian framework.
